












1394Older Age But Not Donor Health Impairs Allogeneic
Granulocyte Colony-Stimulating Factor (G-CSF)
Peripheral Blood Stem Cell Mobilization
Elie. Richa,1 Mona Papari,1 JoAnn Allen,2 Guadalupe Martinez,2 Amittha Wickrema,2
John Anastasi,1 Koen Van Besien,2 Andrew Artz2We evaluated stem cell mobilization in 195 consecutive sibling donors who underwent a uniform mobiliza-
tion regimen of granulocyte colony-stimulating factor (G-CSF) at 10 mg/kg/day divided into twice daily dosing.
On day 5, peripheral blood (PB) CD34 cells/mL were measured immediately prior to peripheral blood stem
cell (PBSC) apheresis. Failed mobilization was defined as\20 CD34 cells/mL on day 5. Themedian agewas 52
years and 73 (37%) were 55 years or greater. Comorbid conditions by the Charlson Comorbidity Index
(CCI) occurred in 13%, but only 3% had Karnofsky performance status (PS)\100%. Eight (4%) failed mobi-
lization, defined as \20 CD34 cells/mL on day 5. Older age was associated with fewer CD34 cells/mL
(P5.002). In addition, 6/73 (8.2%) older donors failed mobilization compared to 2/122 (1.6%) younger
donors (P5.054). Comorbidity, sex, race, and donor weight did not influence mobilization. Although low
PS was very uncommon, it was associated with reduced mobilization (P5.021), but not mobilization failure.
A small fraction of older donors mobilize poorly, and this is not explained by standard measures of comor-
bidity or PS.
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Increasingly, allogeneic hematopoietic cell trans-
plantation (HCT) has been applied to older patients.
A natural consequence of transplanting older recipi-
ents is the need to consider older siblings as donors,
who may have concomitant chronic health conditions
related to aging. The ready availability and safety of
granuloctye colony-stimulating factor (G-CSF) mobi-
lized peripheral blood stem cell (PBSC) collection
[1-3] further promotes collection of older and possibly
less healthy donors. PBSC have surpassed bone mar-
row (BM) as the primary graft source, and are often
preferred among older adults [4,5]. Volunteer unre-
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6/j.bbmt.2009.07.005because of either the delay in procuring donors or
the inability to find donors for others.
Higher PBSCCD34 yields per recipient weight are
linked to faster hematopoietic engraftment and better
transplant outcome [6,7], and an adequate PBSC
apheresis yield of CD34 cells is commonly accepted
as successful mobilization. Most, but not all studies,
have suggested older age reduces PBSC apheresis
yields [8-15]. The post G-CSF preapheresis peripheral
blood (PB) CD34 count reliably predicts collection
yields [2], and when considering donor mobilization
ability, has the advantage of not being influenced by
apheresis factors that affect PBSC yields. Some
[12,16], but not all [17], studies suggest older age
reduces post-G-CSF preapheresis CD34 counts. Prior
studies on the impact of donor age on CD34 yields or
preapheresis CD34 counts have been confounded by
different mobilization regimens, cytokine dose and
type, and a paucity of older donors in many studies.
Whether health conditions more frequently encoun-
tered among older donors predispose to poormobiliza-
tion related to older age also remains unexplored.
We took advantage of our cohort of uniformlymo-
bilized sibling donors that represented a wide age
range, to address the influence of older age on PBSC
mobilization and to test whether donor health might
account for age-related changes in mobilization.
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Donors
We obtained institutional review board (IRB) ap-
proval to retrospectively review the records of PBSC
sibling donors mobilized at the University of Chicago
Medical Center from January 2001 until April 2008.
All donors were evaluated by the adult allogeneic
transplant program. Rare donors underwent 2 mobili-
zations, often in case of disease recurrence in the recip-
ient. In such cases only the first mobilization was
considered. The standard evaluation included a his-
tory, physical examination, and laboratory testing.
We extracted comorbidity, performance status, race,
and weight from the medical record. Comorbidity
was tabulated using the Charlson Comorbidity Index
(CCI) [18,19] and performance status (PS) recorded
by the Karnofsky Performance Status Scale.Table 1. Characteristics of Donors (N 5 195)
Characteristic Value [range] Number (%)
Age, years
Median, mean, range 52, 49, [17-71]
$ 55 122 (63)






Not available 17 (9)
Charlson Comorbidity Index
0 158 (81)
$ 1 24 (12)
Not available 13 (7)
Karnofsky Performance StatusMobilization Regimen
Donors were mobilized with a uniform regimen of
G-CSF (filgrastim; Amgen, Thousand Oaks, CA) at
10 mg/kg/day given twice daily as a subcutaneous
injections of 5 mg/kg. Doses were rounded to vial sizes
of 300 mg or 480 mg. The precise G-CSF dose admin-
istered was not available, but different vial sizes were
used when needed for the same patient to obtain the
goal of 10 mg/kg/day. On day 5, a PB sample was ana-
lyzed for CD34 content prior to G-CSF for day 5.
Leukapheresis was initiated without awaiting PB
CD34 results, knowing that day 5 is the peak CD34/
mL [12]. CD34 cells were enumerated by a fluores-
cence-activated cell sorter (FACS). To quantify poor
PBPC mobilization, we defined mobilization failure
as\20 CD34 cells/mL in the PB on day 5 consistent
with prior publications [12,16]. However, this did
not preclude leukapheresis. Leukapheresis aimed for
a target of $5 106 CD34 cells per kg of recipient
weight. Various machines were used. The majority of
PBSC collections used a Cobe Spectra. Other
machines used for collection included Fresenius AS
104 and Baxter CS 3000. The processing volume and
number of collections varied.100% 173 (89)
80%-90% 6 (3)
Not available 16 (8)




Day 5 preapheresis PB CD
34/mL
Median, mean, range 73.7, 88.2 [2.0-422]
< 20 8 (4)
< 30 16 (8)
Total CD34 yield 106/kg
Median, per donor weight 6.56
Median, per recipient weight 6.8
b.i.d. indicates twice daily; G-CSF, granulocyte colony-stimulating factor;
PB, peripheral blood.
*Rounded to vial size of 300 mg or 480 mg.Mobilization Failure
Statistical analysis
Descriptive statistics were first performed. We
then focused on post G-CSF preapheresis PB CD34
counts/mL as a continuous variable. Because CD34
was not normally distributed when interrogated by
the 1 sample Kolmogorov-Smirnov test, the effect of
predictor variables was primarily tested by the
Mann-Whitney test and P values generated. The
Kruskal-Wallis rank test allowed comparisons of
more than 2 groups. Significance tests and theappropriate 2-tailed P values were derived from
Fishers Exact test for proportions. Statistical analysis
was performed with Stata/SE 10.0 (StataCorp LP,
College Station, TX).RESULTS
Donor Characteristics
Table 1 summarizes baseline donor characteristics.
The median age was 52 years, ranging from 17 to 71
years. Donors 55 years and older accounted for 37%
of subjects. Eighty percent were White and 9% were
African American (AA). The median donor weight
was 86.3 kg, with adults $55 years being slightly
heavier than younger donors (P5 .025).
Comorbid Conditions and PS
Among the 182 patients evaluable for comorbidity,
24 donors had a total of 28 comorbid conditions by the
CCI. Diabetes represented the majority of the comor-
bid conditions (n5 15, 54%), followed by cardiac
(n5 4) and pulmonary (n5 4) abnormalities. Adults
$55 years had more comorbid conditions (16/68,
23.5%) compared to younger adults (8/114, 7.0%)
(P5 .003). Only 6 of 173 evaluable subjects had a PS
\100%; these 6 subjects all had PS rated as 80% to
90%. A PS\100% was more frequent among older
Figure 1. Impact of Donor Age on Progenitor Cell Mobilization.
Table 3. Influence of Clinical Factors on G-CSF Progenitor
Cell Mobilization
Day 5 Preapheresis PB CD34 cells
Mobilization Failure,
<20/mL
Risk Factor* Number Mean P Value† Number (%) P Value
Age, years .002 .054
< 55 73 97.6 2 (1.6)
$ 55 122 72.6 6 (8.2)
Sex .44 .99
Male 105 92.7 4 (3.8%)
Female 90 83.0 4 (4.4%)
Race .12 .99
White 142 84.7 8 (5.9%)
African-American 16 102.5 0 (0%)
Comorbidity .41 .60
CCI5 0 158 89.8 8 (5%)
CCI $1 24 79.1 0 (0%)
Karnofsky PS .021 .24
100% 173 89.2 7 (4%)
80%-90% 6 50.5 1 (16.7%)
Median donor weight, .81 .72
Below 88 91.0 3 (3%)
Above 87 78.9 5 (6%)
G-CSF, granuloctye colony-stimulating factor; PS, performance score;
PB, peripheral blood; CCI, Charlson Comorbidity Index.
*Number of evaluable patients differs for risk factors.
†Mann-Whitney test.
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0.9%) (P5 .03).
Mobilization
The median and mean post-G-CSF preapheresis
day 5 CD34 cells were 73.7 cells/mL and 88.2/mL, re-
spectively. Failure of mobilization, defined as
CD34\20/mL, occurred in 8/195 donors (4.1%).
Twice as many (8.2%) had \30 CD34/mL. The
median apheresis yield was 6.6 106 CD34 cells per
donor weight and 6.8 106 CD34 cells per recipient
weight. More than 1 day of collection was required
in 49.2% of donors. Seven of 175 (4%) had yields
\2.0 106 CD34 cells/kg in recipient weight and
47/175 (26.8%) had fewer than 5 106 CD34 cells/kg
in recipient weight. Confirming the utility of day 5
preapheresis CD34\20/mL as a predictor, 3 of the 8
donors with \20/mL CD34 collected \2.0 106
CD34/kg in recipient weight and none reached
5 106 CD34/kg recipient weight.
Predictors of Mobilization
Age heavily influenced mobilization. Figure 1
depicts CD34 counts by age, showing reduced average
CD34 counts with advancing age. Table 2 quantifies
the effect of each decade of age on CD34/mLTable 2. G-CSF Progenitor Cell Mobilization by Donor Age




Donors Mean Median < 20 (%) Range
<30 8.7 109.8 122.5 0 (0) 23.0-247.5
30-39 13.8 111.2 93.5 1 (3.6) 11.0-237.6
40-49 22.5 94.6 84.4 0 (0) 23.4-247.5
50-59 45.9 81.4 68.4 5 (6.7) 5.6-421.9
$60 17.4 65.7 57.8 2 (7.1) 2.0-181.9
G-CSF indicates granulocyte colony-stimulating factor; PB, peripheral
blood.(P5 .004) and on mobilization failure. Table 3 de-
scribes the influence of clinical predictors on CD34
counts as a continuous variable and on mobilization
failure defined as CD34\20/mL. Adults 55 years
and older had significantly lower CD34 counts
(P5 .002) and were more likely to experience mobili-
zation failure (P5 .03). Among the 16 AA donors, the
mean CD34 count of 102.5/mL did not statistically dif-
fer from the 84.7/mL found among Whites (P5 .12).
None of the AA donors failed to mobilize.
Sex, comorbidity, and donor weight did not have
an impact on CD34 counts or the incidence of mobili-
zation failure. Interestingly, none of the 8 donors who
failed mobilization had comorbid conditions by the
CCI. The mean CD34 count for those with PS of
100% was 89.2/mL compared to 50.5/mL for the 6 do-
nors with impaired PS. Thus, lower PS was associated
with lower PB CD34 (P5 .021). Only 1 of the 8 poor
mobilizers had a PS\100%, and, therefore, PS was
not a predictor for mobilization failure. Although im-
paired PS was uncommon, we sought to exclude lower
PS accounting for the age-related reduction in mobili-
zation. In a stratified analysis, older age continued to
predict for lower CD34 counts among those with
a PS of 100% (P\ .001). Among the 16 donors with-
out PS recorded, the mean CD34 was 91.3/mL, similar
to those with a PS of 100%, arguing against a bias in
this subgroup.
Older age was associated with a greater chance of
requiring more than 1 day of collection (P5 .017).
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HLA-compatible sibling donors have traditionally
been considered the optimal hematopoietic stem cell
(HSC) donor because of their immediate availability
and superior outcomes compared to unrelated donors.
As the median age of allogeneic HCT recipients has
risen, questions regarding the desirability of collecting
older sibling donors have emerged. Debate has focused
to what extent if any older age reduces PBSC apheresis
yields [8-15] and/or post-G-CSF preapheresis CD34
counts [12,16,17].
We confirmed the impact of age on G-CSF PBSC
mobilization and report on the prevalence and influ-
ence of donor health on mobilization. We selected
2001 as a start date, because this is when we introduced
a reduced intensity conditioning (RIC) regimen, facil-
itating transplantation of older adults. A uniform mo-
bilization regimen and standard measurement of day 5
preapheresis CD34 enabled us to study donor factors
affecting mobilization independent of apheresis vari-
ables such as volume of blood processed, collection
machines, and collection efficiency.
We found a mean CD34 of 88/mL, similar to the
mean of 84/mL reported by Vasu and colleagues [16]
among donors to whom they gave 10 mg/kg/day of
G-CSF. In addition, the 4.1% (8/195) incidence of
mobilization failure, defined as\20/mL [12,16], was
exactly the same among the 639 donors described by
Vasu. The median CD34 of 74/mL was slightly higher
than reported by de Lavallade et al. [17], who reported
amedianof 59.5/mL,but their studyemployeda slightly
lower average G-CSF dose of 8.9 mg/kg/day. The data
confirm preapheresis CD34 as a reproducible measure
of mobilization capacity. We recommend future stud-
ies assessing biologic features of mobilization include
post-G-CSF preapheresis CD34 results to isolate do-
nor factors from collection variables.
Our data show a strong association of older donor
age of 55 years or more (P5 .002), and of age by
decade (P5 .004) with reduced mobilization. In addi-
tion, the incidence of mobilization failures was 8.2%
among adults 55 years and older compared to 1.6%
among younger donors (P5 .054). Our data confirm
the impact of age on mobilization reported by Vasu
et al.[16]. By contrast, de Lavallade and colleagues
[17] did not find that donors 55 years and over had
reduced mobilization. The discordant results are not
easily explained, but may relate in part to having only
44 older donors in their cohort compared to our
cohort of 73 older donors.
No studies have assessed why older donors do not
mobilize as well. Intuitively, one may suspect that
chronic health conditions, which occur more often
among older adults, might impair mobilization. As ex-
pected, older donors did harbormore comorbid condi-
tions (24%) relative to younger adults (7%) as assessedby the charslon comorbidity index (P5 .003). Only 6
donors had a Karnofsky performance status (PS)
\100%, although PS limitations were generally re-
stricted to older adults 5/68 (7.4%) (P5 .03 for differ-
ence with younger donors). Perhaps surprisingly, the
presence of comorbidity had no association with
CD34/mL (P5 .41) and none of the 8 donors who
failed to mobilize had comorbid conditions. Impaired
PS was associated with lower CD34, but not mobiliza-
tion failure. Older age strongly predicted lower mobi-
lization when only analyzing donors with normal PS.
To our knowledge, only 1 report has evaluated comor-
bidity among allogeneic donors [9]. Both older age and
comorbid conditions were more common among
those with poor PBSC yields. No further analysis
was performed, and the authors concluded older age
impairs PBSC yields.
Our data provide important baseline data about
health status of sibling donors in the modern era, and
should facilitate planning future studies related to do-
nor health impairments. Unrelated donor registries
have fairly rigid guidelines for donation including
age\60 years (www.psbc.org/programs/marrow_gui
delines.htm) and permanent deferral if receiving
a medication for diabetes [20]. Not surprisingly, in
the national marrow donor registry, only 9% of
PBSC donors were 51 to 60 years of age [3]. In con-
trast, 54% of our donors were over 50 years of age,
14.6% 60 years and older, and 8% had diabetes. The
unrelated donor guidelines would have excluded a con-
siderable fraction of our donors. It has been suggested
to screen older sibling donors for comorbidity [21],
although the acceptable age and comorbid conditions
for related donors are determined by donor centers.
Although highly controversial, it remains unproven
that older donor age worsens recipient outcomes
[22-25]. Our data suggest that centers should not
exclude sibling donors on the basis of age or certain co-
morbid conditions, simply for fear of poor mobiliza-
tion. Further study on the impact of older age and
comorbid conditions on donor adverse events and re-
cipient outcomes such as hematopoietic engraftment,
immune reconstitution, and survival are sorely needed.
Several additional limitations are worth noting.
Most importantly, the CCI [18], although a highly val-
idated and widely used tool, only captures common
comorbid conditions recorded in the history. More
comprehensive measures of comorbid conditions, in-
cluding medications and alcohol that might hinder
hematopoietic function, warrant study. The HCT-
comorbidity index has been applied to transplant re-
cipients, but most of the comorbid conditions are
related to objective tests not indicated in donors (eg,
pulmonary function tests) and/or conditions recorded
by the CCI [26]. We believe more sensitive measures
of functional status hold the most promise. Although
very few patients had a PS \100%, there was
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Simple and more discriminative measures of func-
tional status such as walk speed or grip strength should
be explored [27-29]. Aside from limitations in the in-
struments themselves, it is likely that some HLA-com-
patible donors were excluded for comorbidity, age,
and/or functional limitations either at the time of do-
nor evaluation or were not even HLA-typed.
The precise defects that impair mobilization or
result in mobilization failure remain of both practical
and biologic interest. Age-related deficiencies in
HSCs number seem unlikely, considering preclinical
data showing older mice mobilize HSCs and progeni-
tor cells more efficiently after G-CSF than younger
mice [30]. Moreover, older mice generally have similar
or greater numbers of HSCs relative to younger mice
[31]. We concur with Vasu and colleagues [16], who
speculated that genetic variation may influence stem
cell mobilization. We further postulate that the inter-
action of genetic predisposition and advancing age cul-
minates in mobilization failure. Although HSC
quantity may be adequate with aging, understress,
functional impairments in aged HSCs can be identi-
fied, possibly resulting from DNA damage [32]. Clin-
ical results further support a genetic contribution to
mobilization. Remobilization of the same donors leads
to strikingly similar yields, whereas interindividual
variation in mobilization is quite wide [33,34]. In addi-
tion, mobilization appears to differ by race. Vasu and
colleagues [16] described significantly greater prea-
pheresis CD34 of 104 for AA compared to 79 for
Whites. In our data, the mean preapheresis CD34
count of 102.5 among AAs was considerably greater
than that of 84.7 for Whites; however, the difference
was not significant, owing to a small number of AA do-
nors. This racial difference might even explain the
lower CD34 counts found in a recent study of Italian
donors [17].
In conclusion, older age impairs G-CSF PBSC
mobilization, but older adults usually mobilize ade-
quately. The presence of comorbidity does not predict
for worse mobilization, but the few donors with
impaired PS may not mobilize as well.ACKNOWLEDGMENTS
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